Images List Premium Download Classic

Antagonist

Antagonist-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
NEW Use of il-31ra monoclonal antibodies for antagonizing signal transduction in dorsal root ganglion cells
Zymogenetics, Inc.
February 15, 2018 - N°20180044426

Use of antagonists to il-31ra and osmrb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
NEW Combination of a pd-1 antagonist and vorinostat for treating cancer
Merck Sharp & Dohme Corp.
February 15, 2018 - N°20180044418

The present disclosure describes combination therapies comprising an antagonist of programmed death 1 receptor (pd-1) and suberoylanilide hydroxamic acid (saha), and the use of the combination therapies for the treatment of caner.
NEW Methods and compounds useful in the synthesis of orexin-2 receptor antagonists
Eisai R&d Management Co., Ltd.
February 15, 2018 - N°20180044285

The present disclosure provides compounds and methods that are useful for the preparation of compounds useful as orexin-2 receptor antagonists.
NEW Antagonist Patent Pack
Download 805+ patent application PDFs
Antagonist Patent Applications
Download 805+ Antagonist-related PDFs
For professional research & prior art discovery
inventor
  • 805+ full patent PDF documents of Antagonist-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
NEW Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
Galectin Therapeutics, Inc.
February 15, 2018 - N°20180042958

Methods and compositions for reducing fibrosis and cirrhosis are provided in which an effective dose of an admixture of a polysaccharide compound and, for example, a compound selected from the group consisting of antibodies specific to intracellular or cell-surface: (i) beta-pdgf receptors; (ii) synaptophysin; (iii) zvegf3; (iv) ccr1 receptors; (v) connective tissue growth factor; (vi) alpha 1-smooth muscle actin; (vii) ...
NEW Phenyl derivative
February 15, 2018 - N°20180042908

Wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human s1p2 antagonistic activity. The compound may therefore be used as a therapeutic agent for s1p2-mediated diseases such as diseases resulting from vascular constriction, fibrosis, and respiratory diseases.
NEW V1b receptor antagonist for use in the treatment of patients having an elevated avp ...
Max-planck-gesellschaft Zur Förderung Der Wissenschaften E.v.
February 15, 2018 - N°20180042898

The present invention relates to a vasopressin receptor 1b (v1b) antagonist for use in the treatment of depressive symptoms and/or anxiety symptoms in patients showing an elevated arginine vasopressin (avp) level and/or an elevated copeptin level. The present invention further relates to a method for predicting the treatment response to a v1b antagonist in patients with ...
NEW Antagonist Patent Pack
Download 805+ patent application PDFs
Antagonist Patent Applications
Download 805+ Antagonist-related PDFs
For professional research & prior art discovery
inventor
  • 805+ full patent PDF documents of Antagonist-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
NEW Methods of treating cancer
Mitchell Woods Pharmaceuticals, Inc.
February 15, 2018 - N°20180042867

Methods of regulating disorders and diseases by inhibiting glycolysis within cells, including cancer cells, include administration of a compound that is one or more of: an antagonist of gpr55, an agonist of β2-adrenergic receptor (ar), or a compound that decreases expression and activity of egfr, thereby reducing glycolysis in cancer cells. In embodiments, the compound is a fenoterol ...
NEW Tamper resistant oral opioid agonist formulations
Purdue Pharma L.p.
February 15, 2018 - N°20180042859

Oral dosage forms containing an opioid antagonist in a sequestered form are described. The opioid antagonist is sequestered such that it is not released or substantially not released in the gastrointestinal tract from the dosage form which is administered orally intact. However, when the dosage form is chewed, crushed, heated or dissolved in a solvent, and then administered orally, intranasally, ...
NEW Immuno-regulatory lipid containing spherical nucleic acids
Exicure, Inc.
February 15, 2018 - N°20180042848

Immunoregulatory spherical nucleic acids (irsnas) composed of a lipid containing core and an inert nucleic non-tlr antagonistic oligonucleotide shell are provided. Acid shell these it-snas are useful for modulating an immune response.
Rotorcraft vibration suppression system in a four corner pylon mount configuration
Bell Helicopter Textron Inc.
February 08, 2018 - N°20180038439

The vibration suppression system includes a vibration isolator located in each corner in a four corner pylon mount structural assembly. The combination of four vibration isolators, two being forward of the transmission, and two being aft of the transmission, collectively are effective at isolating main rotor vertical shear, pitch moment, as well as roll moment induced vibrations. Each opposing pair ...
Anti-factor b antibodies and their uses
Genentech, Inc.
February 08, 2018 - N°20180037667

The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (cnv) and age-related macular degeneration (amd), by administration of factor b antagonists.
Therapeutic and diagnostic methods for cancer
Genentech, Inc.
February 08, 2018 - N°20180037655

The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a pd-l1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising ...
Tlr7/8 antagonists and uses thereof
Merck Patent Gmbh
February 08, 2018 - N°20180037570

The present invention relates to compounds of formula i and pharmaceutically acceptable compositions thereof, useful as tlr7/8 antagonists.
Antagonist Patent Pack
Download 805+ patent application PDFs
Antagonist Patent Applications
Download 805+ Antagonist-related PDFs
For professional research & prior art discovery
inventor
  • 805+ full patent PDF documents of Antagonist-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Aminoquinazoline compounds as a2a antagonist
Merck Sharp & Dohme Corp.
February 08, 2018 - N°20180037554

The present invention is directed to compounds of generic formula i: or pharmaceutically acceptable salts thereof that are believed to be useful as an a2a-receptor antagonist.
Nmda antagonist prodrugs
Astrazeneca Ab
February 08, 2018 - N°20180037550

Prodrugs of an nmda antagonist, (s)-1-phenyl-2-(pyridin-2-yl)ethanamine, useful for the treatment of depression (particularly major depressive disorder) or pain; compositions comprising them, and methods of making them.
Compounds and compositions for the treatment of ocular disorders
Graybug Vision, Inc.
February 08, 2018 - N°20180036416

The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.
Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
180 Therapeutics Lp
February 08, 2018 - N°20180036404

The subject invention provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of an il-33 antagonist effective to treat the patient. The subject invention also provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of a ...
Method for preventing and/or treating infections, colonisations, or illnesses related to staphylococcus aureus, pseudomonas ...
Laboratoires Urgo
February 08, 2018 - N°20180036356

The subject matter of the present invention is a bacterium or a mixture of bacteria having an antagonistic activity with respect to strains of s. Aureus, p. Aeruginosa, streptococcus pyogenes, enterococcus faecium, enterobacter cloacae, proteus mirabilis, bacteroides fragilis, staphylococcus epidermidis, propionibacterium acnes, candida albicans and/or malassezia furfur as well as the use thereof in the treatment and/or prevention ...
Novel c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity
The University Of Maryland, Baltimore
February 08, 2018 - N°20180036320

Described are steroidal c-17 benzoazoles, pyrimidinoazoles (azabenzoazoles) and diazines. Methods for their synthesis are also described, which include methods having a step of nucleophilic vinylic “addition-elimination” substitution reaction of 3β-acetoxy-17-chloro-16-formylandrosta-5,16-diene or analogs thereof and benzoazole or pyrimidinoazole nucleophiles and methods having a palladium catalyzed cross-coupling reaction of 17-iodoandrosta-5,16-dien-3β...
The University Of Chicago
February 08, 2018 - N°20180036318

Methods are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.
Pharmaceutical for prophylaxis or treatment of hypertension
Daiichi Sankyo Company, Limited
February 08, 2018 - N°20180036281

A pharmaceutical for the prophylaxis or treatment of hypertension or a disease derived from hypertension. The pharmaceutical is characterized by comprising (i) a specific mineralocorticoid receptor antagonist and (ii) one or more components selected from the following components (a) to (c), for administration simultaneously or separately at a time interval: (a) an angiotensin ii receptor antagonist, (b) a calcium antagonist, ...
Loading